|Bid||118.37 x 100|
|Ask||124.99 x 300|
|Day's Range||123.47 - 123.88|
|52 Week Range||99.81 - 123.88|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
When it comes to single-factor investing, growth and momentum ETFs have performed very well this year, and have attracted significant assets along the way. The lineup of growth and momentum ETFs, however, couldn’t be more different, making choosing a fund to ride the wave potentially tricky. From a performance perspective, both growth and momentum are benefiting from a slow-and-steady economy, according to Russ Koesterich, portfolio manager for BlackRock’s Global Allocation team.
In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.
On June 5, 2017, Edwards Lifesciences’ Sapien 3 valve was approved by the FDA for use in the aortic and mitral valve-in-valve procedure.
Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.
In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis ...
Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design.
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
Taking advantage of one of the greatest benefits of ETFs—transparency—can lead to some surprising discoveries. Case in point: the world of small-cap ETFs. We’ve discovered that while a number of ETFs call themselves “small-caps,” they really don't have that much small-cap exposure. And that matters, because a fund that isn’t exactly small-cap is going to deliver different risks and different returns than a pure small-cap strategy. Clarifying Terms
The Zacks Analyst Blog Highlights: iShares Core S&P Mid-Cap ETF, iShares Russell Mid-Cap ETF, Vanguard Mid-Cap Growth ETF, iShares S&P Mid-Cap 400 Growth ETF and Schwab U.S. Mid-Cap ETF
Mid-cap ETFs are arguably safer options and have the potential to move higher in turbulent times, especially if political issues or financial instability creeps into the picture.
Under Armour is currently struggling to meet investors' expectations, as it missed analysts' estimates in 4Q16. It reported a 12% rise in revenue in the quarter, missing expectations.
On January 3, 2017, Piper Jaffray downgraded Michael Kors Holdings’s (KORS) rating from “overweight” to “neutral.” It also lowered the stock’s price target from $60.00 to $48.00 per share.
Michael Kors Holdings (KORS) has a market cap of $7.7 billion. It fell 5.1% to close at $47.16 per share on November 14, 2016.
Michael Kors Holdings (KORS) has a market cap of $9.0 billion. It rose 3.2% to close at $51.76 per share on November 10, 2016.